stockrowGrace Therapeutics, Inc.
GRCE Healthcare Biotechnology
- EPS
- −333.3%
- Free cash flow
- −78.9%
Quarter to June 2026, against a year earlier
Follow GRCE
Alert me
Grace Therapeutics, Inc. (GRCE) EV/Sales
As of 6 November 2026, Grace Therapeutics, Inc. (GRCE) trades at a EV/Sales of 106×. Over the past ten years it has ranged from −84.3× (December 2022) to 27,374× (December 2019); the current reading is higher than 34% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 66.5× | (89.62%) |
| FY2016 | 640× | 1,799.15% |
| FY2016 | 33.7× | (80.09%) |
| FY2015 | 169× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2021 | 66.5× | (22.93%) |
| Dec 2020 | 86.3× | (93.41%) |
| Nov 2016 | 1,308× | 83.40% |
| Aug 2016 | 713× | 0.35% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| PTHS Pelthos Therapeutics Inc. compare | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 24.6× |
| GRCE Grace Therapeutics, Inc. | 106× |
| IBO Impact Biomedical Inc. compare | 1,228× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)